A first-in-human vaccine targeting the KRAS gene — one of the most commonly mutated drivers of pancreatic cancer — has proven safe and triggered robust immune responses in 90% of high-risk participants, marking the earliest proof of concept that cancer interception via vaccination is actually possible in humans.

Vital Signs

Key numbers from the Phase I trial:

• 90% of high-risk participants developed KRAS-specific T-cell responses
• 0 participants developed...